Time for an Oregon psilocybin licensing discussion update. Ballot Measure 109 gave the Oregon Health Authority (“OHA”) two years to create regulations for the manufacturing, testing, sale, and supervised administration of psilocybin. This two-year development phase started on January 1, 2021, and on March 18 Governor Kate Brown appointed members to the Oregon Psilocybin Advisory
Psychedelics developments in 2021 covered everything from legalization and decriminalization to pharmaceutical advances and public company milestones.
On Monday, November 13, 2021, New York Assemblyman Pat Burke introduced medical psilocybin legislation. The “purpose or general idea of bill” provides a good summary: this legislation would “create psilocybin service centers to provide innovative treatment options for ailments such as PTSD, depression, alcohol dependency, anxiety, among others.” The bill echoes two separate pieces of
DMT, or N, N-dimethyltryptamine is a powerful psychedelic. DMT, like its sister psychedelics (LSD, MDMA, psilocybin … and even marijuana), is a Schedule I controlled substance. So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back
In April of this year, Florida’s first attempt at psychedelics reform failed, as a House subcommittee rejected HB 549. This bill, introduced by Rep. Michael Grieco (D-Miami Beach), would have legalized the use of psilocybin for mental treatment in the nation’s third most populous state. Despite this setback, 2021 could yet be a pivotal year
Cannabis is legal and regulated in most U.S. states. Oregon legalized and will soon regulate psilocybin. Cities around the country decriminalized (and more are decriminalizing) a host of other psychedelics. Ketamine clinics are popping up around the county. Next up is MDMA (referred to in some forms as “ecstasy”). Today, we’re going to talk about
Microdose hosted its annual psychedelics conference in Miami last week (appropriately titled “Wonderland”). We were there, meeting industry insiders and clients, and keeping on the cutting edge of the psychedelics space. For our readers who weren’t able to make it, here are some of our key takeaways from two days of all things psychedelics: Everyone
Can companies in the psychedelic space register their trademarks, for psychedelics themselves? This is a question that often comes up, given U.S. trademark law’s requirement that marks be lawfully used in commerce as a precondition to registration. In recent times, many trademark applications filed by cannabis businesses have been refused on lawful-use grounds, though this
Something strange happened yesterday. Psychedelics unicorn Compass Pathways released data for the largest clinical trial ever conducted of a psilocybin drug. Not only did the drug seem to work, but the heavily anticipated data were “breathtaking” in the words of Compass’ CEO. Immediately, the company’s publicly traded shares dropped 16%. Including the day prior, it
Public and scientific interest in psychedelics such as psilocybin and MDMA is expanding. Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Psilocybin, a
